These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30855193)

  • 21. [Immunological evaluation for CML and its possibility for an immunotherapy].
    Fujii S
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Aug; 32(4):231-41. PubMed ID: 19721343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leukemia Stem Cells in Chronic Myeloid Leukemia.
    Shan Y; DeSouza N; Qiu Q; Li S
    Adv Exp Med Biol; 2019; 1143():191-215. PubMed ID: 31338821
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function.
    Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X
    Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
    Schwartz J; Pinilla-Ibarz J; Yuan RR; Scheinberg DA
    Semin Hematol; 2003 Jan; 40(1):87-96. PubMed ID: 12563615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells.
    Naka K; Hoshii T; Hirao A
    Cancer Sci; 2010 Jul; 101(7):1577-81. PubMed ID: 20491777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definition of immunogenic antigens in chronic myeloid leukemia (CML) towards the development of cancer vaccines.
    Schmitt M; Greiner J
    Leuk Res; 2005 Dec; 29(12):1367-9. PubMed ID: 16135383
    [No Abstract]   [Full Text] [Related]  

  • 27. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents.
    Talati C; Pinilla-Ibarz J
    Curr Opin Hematol; 2018 Mar; 25(2):154-161. PubMed ID: 29266016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and molecular monitoring update in chronic myeloid leukemia management.
    Sorel N; Cayssials É; Brizard F; Chomel JC
    Ann Biol Clin (Paris); 2017 Apr; 75(2):129-145. PubMed ID: 28377326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
    Hus I; Tabarkiewicz J; Lewandowska M; Wasiak M; Wdowiak P; Kusz M; Legieć M; Dmoszyńska A; Roliński J
    Folia Histochem Cytobiol; 2011; 49(1):153-60. PubMed ID: 21526503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.
    Warda W; Larosa F; Neto Da Rocha M; Trad R; Deconinck E; Fajloun Z; Faure C; Caillot D; Moldovan M; Valmary-Degano S; Biichle S; Daguindau E; Garnache-Ottou F; Tabruyn S; Adotevi O; Deschamps M; Ferrand C
    Cancer Res; 2019 Feb; 79(3):663-675. PubMed ID: 30514753
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U; Schwarzer R; Jahn B; Sroczynski G; Kluibenschaedl M; Wolf D; Radich J; Brixner D; Gastl G; Siebert U
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [State-of-the-art management of CML in 2015 and future prospects].
    Kimura S
    Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors--a synthesis of clinical and laboratory data.
    Irvine DA; Heaney NB; Holyoake TL
    Blood Rev; 2010 Jan; 24(1):1-9. PubMed ID: 20005615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosing and managing advanced chronic myeloid leukemia.
    Deininger MW
    Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.
    Copland M; Fraser AR; Harrison SJ; Holyoake TL
    Cancer Immunol Immunother; 2005 Apr; 54(4):297-306. PubMed ID: 15692843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.
    Gannagé M; Abel M; Michallet AS; Delluc S; Lambert M; Giraudier S; Kratzer R; Niedermann G; Saveanu L; Guilhot F; Camoin L; Varet B; Buzyn A; Caillat-Zucman S
    J Immunol; 2005 Jun; 174(12):8210-8. PubMed ID: 15944330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular biology and treatment of CML].
    Kimura S
    Rinsho Ketsueki; 2017; 58(10):1920-1930. PubMed ID: 28978834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.